With SITC fast coming up this week, immunotherapies in all sorts of shapes and guises are very much going to be at the forefront of many people’s attention.
Aside from various well established approaches though, is there anything new on the horizon?
It turns out there is something that caught our imagination at BSB.
The good news it’s not yet another X checkpoint inhibitor/immune agonist/cytokine – this concept is both a novel and a compelling one.
It also potentially fills a need not addressed by the other approaches.
Want to learn more about this intriguing approach based on rationally driven science?